Reading-based lawyers from law firm Osborne Clarke have advised NeRRe Therapeutics on its £20 million Series B2 financing round. The financing involved a syndicate of leading transatlantic life sciences investors led by a new investor Columbus Venture Partners and existing investors Advent Life Sciences, Fountain Healthcare Partners, Forbion Capital Partners and OrbiMed.
The Osborne Clarke team was led by corporate and venture capital partner Justin Starling (pictured) and associate director Elizabeth Yell.
NeRRe Therapeutics is a clinical stage company developing orvepitant, its wholly owned neurokinin-1 (NK-1) antagonist, as a first in class treatment for disabling chronic cough caused by reflex hypersensitivity disorders.
The proceeds from the financing round will primarily be used to fund the Phase 2 clinical development of orvepitant as a treatment for chronic cough associated with IPF.
Bristol engineering design consultants Hydrock has been acquired by Stantec. Hydrock has over 950 employees…
Plans from waterside developers Peel Waters to build a new business campus at Chatham Docks…
Europa Road has signed a contract with DPD Netherlands to run new daily line hauls…
Pure Human Resources, an HR, recruitment and training consultancy based in North Baddesley, Hampshire, is…
The Science Based Targets initiative (SBTi) has approved the near-team emissions reduction targets of medical…
Bagshot-based real estate investor and developer Sixpenny Group has acquired a 45,000 sq ft residential-led…